Initial Evidence of the Beneficial Effects of Glutamate-Modulating Agents in the Treatment of Self-Injurious Behavior Associated With Borderline Personality Disorder
J Clin Psychiatry 2005;66(11):1492-1493 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
Self-injurious behavior (SIB) in patients with borderline
personality disorder (BPD), especially cutting, represents a
serious and often intractable clinical problem.1
There are few
validated pharmacologic strategies for managing SIB.1–3
describe our initial experience using glutamate-modulating
agents in 2 patients with BPD and prominent SIBs.